|
PCBP1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.33689999965081E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.235480E-04 |
| Normal-vs-Stage2 |
1.802470E-03 |
| Normal-vs-Stage3 |
7.07879999950478E-07 |
| Normal-vs-Stage4 |
2.73269999961911E-07 |
| Stage1-vs-Stage2 |
5.032000E-01 |
| Stage1-vs-Stage3 |
4.023500E-02 |
| Stage1-vs-Stage4 |
4.390400E-02 |
| Stage2-vs-Stage3 |
6.060800E-01 |
| Stage2-vs-Stage4 |
5.884000E-01 |
| Stage3-vs-Stage4 |
9.652400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.85708999999035E-05 |
| Normal-vs-AfricanAmerican |
7.773200E-04 |
| Normal-vs-Asian |
2.247300E-04 |
| Caucasian-vs-AfricanAmerican |
7.279800E-01 |
| Caucasian-vs-Asian |
9.908000E-01 |
| AfricanAmerican-vs-Asian |
7.404600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
6.91849999956418E-07 |
| Normal-vs-Female |
2.02659999999355E-05 |
| Male-vs-Female |
2.900400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.761000E-04 |
| Normal-vs-Age(41-60Yrs) |
4.03649999980438E-07 |
| Normal-vs-Age(61-80Yrs) |
1.52980000001079E-07 |
| Normal-vs-Age(81-100Yrs) |
3.390400E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.462650E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.448400E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.481600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.510000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.544400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
1.123760E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.488000E-01 |
| Classical-VS-Follicular |
2.819000E-01 |
| Classical-VS-Other |
1.773370E-01 |
| Classical-VS-Normal |
1.71205999999202E-05 |
| Tall-VS-Follicular |
9.821200E-01 |
| Tall-VS-Other |
4.202800E-01 |
| Tall-VS-Normal |
1.592770E-04 |
| Follicular-VS-Other |
5.704400E-01 |
| Follicular-VS-Normal |
5.75079999999284E-05 |
| Other-VS-Normal |
1.437310E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.95800000049695E-07 |
| Normal-vs-N1 |
5.69350000034774E-07 |
| N0-vs-N1 |
2.275800E-01 |
|
|
